A Web- and Mobile-Based Intervention for Women Treated for Breast Cancer to Manage Chronic Pain and Symptoms Related to Lymphedema: Randomized Clinical Trial Rationale and Protocol

Mei Rosemary Fu, Deborah Axelrod, Amber Guth, Joan Scagliola, Kavita Rampertaap, Nardin El-Shammaa, Jason Fletcher, Yan Zhang, Jeanna M Qiu, Freya Schnabel, Karen Hiotis, Yao Wang, Gail D'Eramo Melkus, Mei Rosemary Fu, Deborah Axelrod, Amber Guth, Joan Scagliola, Kavita Rampertaap, Nardin El-Shammaa, Jason Fletcher, Yan Zhang, Jeanna M Qiu, Freya Schnabel, Karen Hiotis, Yao Wang, Gail D'Eramo Melkus

Abstract

Background: Despite current advances in cancer treatment, many breast cancer survivors still face long-term post-operative challenges as a result of suffering from daily pain and other distressing symptoms related to lymphedema, ie, abnormal accumulation of lymph fluid in the ipsilateral upper limb or body. Grounded in research-driven behavioral strategies, The-Optimal-Lymph-Flow is a unique Web- and mobile-based system focusing on self-care strategies to empower, rather than inhibit, how breast cancer survivors manage daily pain and symptoms. It features a set of safe, feasible, and easily-integrated-into-daily-routine exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal body mass index (BMI).

Objective: To conduct a randomized clinical trial (RCT) to evaluate the efficacy of the Web- and mobile-based The-Optimal-Lymph-Flow system for managing chronic pain and symptoms related to lymphedema. The primary outcome includes pain reduction, and the secondary outcomes focus on symptom relief, limb volume difference by infra-red perometer, BMI, and quality of life (QOL) related to pain. We hypothesize that participants in the intervention group will have improved pain and symptom experiences, limb volume difference, body mass index, and QOL.

Methods: A parallel RCT with a control-experimental, pre- and post-test, repeated-measures design is used in this study. A total of 120 patients will be randomized according to the occurrence of pain. Participants will be recruited face-to-face at the point of care during clinical visits. Participants in the intervention group will receive the Web- and mobile-based The-Optimal-Lymph-Flow intervention and will have access to and learn about the program during the first in-person research visit. Participants in the control group will receive the Web- and mobile-based Arm Precaution program and will have access to and learn about the program during the first in-person research visit. Participants will be encouraged to enhance their learning by accessing the program and following the daily exercises during the study period. Participants will have monthly online self-report of pain and symptoms at 4 and 8 weeks post-intervention. During the two in-person research visits prior to and 12 weeks post-intervention, participants will be measured for limb volume difference, BMI, and complete self-report of pain, symptoms, self-care behaviors, and QOL.

Results: This trial is currently open for recruitment. The anticipated completion date for the study is July 2017. The primary endpoint for the study is absence or reduction of pain reported by the participants at week 12 post-intervention.

Conclusions: The-Optimal-Lymph-Flow is a unique Web- and mobile-based self-care and patient-reported outcome system designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Patients learn self-care strategies from a Web- and mobile-based program and track their symptoms. The RCT will directly benefit all women treated for breast cancer who suffer from or at risk for pain and symptoms related to lymph fluid accumulation.

Trial registration: Clinicaltrials.gov NCT02462226; https://ichgcp.net/clinical-trials-registry/NCT02462226 (Archived by WebCite at http://www.webcitation.org/6du4IupG5).

Keywords: ache; breast cancer; health behavior; lymphedema; mHealth; pain; soreness; symptoms; tenderness.

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
The CONSORT flow diagram.
Figure 2
Figure 2
The Web- and mobile-based The-Optimal Lymph-Flow.
Figure 3
Figure 3
Video instructions for daily exercises.
Figure 4
Figure 4
Symptom reporting.
Figure 5
Figure 5
Friendly reminder for daily exercises.

References

    1. American Cancer Society (ACS) Breast Cancer Facts & Figures 2014-2015. [2015-12-28]. .
    1. Burckhardt CS, Jones KD. Effects of chronic widespread pain on the health status and quality of life of women after breast cancer surgery. Health Qual Life Outcomes. 2005;3:30. doi: 10.1186/1477-7525-3-30.
    1. Fu MR, Rosedale M. Breast cancer survivors' experiences of lymphedema-related symptoms. J Pain Symptom Manage. 2009 Dec;38(6):853. doi: 10.1016/j.jpainsymman.2009.04.030.
    1. Johansson K, Ohlsson K, Ingvar C, Albertsson M, Ekdahl C. Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study. Lymphology. 2002 Jun;35(2):59–71.
    1. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol. 2005 May 20;23(15):3322–30. doi: 10.1200/JCO.2005.05.130.
    1. Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba Gideon K D. Scott-Conner C. The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol. 2009 Jul;16(7):1959–72. doi: 10.1245/s10434-009-0452-2.
    1. Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):775–82. doi: 10.1158/1055-9965.EPI-06-0168.
    1. Mak SS, Yeo W, Lee YM, Mo KF, Tse KY, Tse SM, Ho FP, Kwan WH. Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong. Nurs Res. 2008;57(6):416–25. doi: 10.1097/NNR.0b013e31818c3de2.
    1. Fu M, Axelrod D, Cleland C, Qiu Zeyuan, Guth Amber A, Kleinman R, Scagliola J, Haber Judith. Symptom report in detecting breast cancer-related lymphedema. Breast Cancer (Dove Med Press) 2015;7:345–52. doi: 10.2147/BCTT.S87854.
    1. Cormier JN, Xing Y, Zaniletti I, Askew RL, Stewart BR, Armer JM. Minimal limb volume change has a significant impact on breast cancer survivors. Lymphology. 2009 Dec;42(4):161–75.
    1. Fu MR, Ridner SH, Hu SH, Stewart BR, Cormier JN, Armer JM. Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011. Psychooncology. 2013 Jul;22(7):1466–84. doi: 10.1002/pon.3201.
    1. Reddick BK, Nanda JP, Campbell L, Ryman DG, Gaston-Johansson F. Examining the influence of coping with pain on depression, anxiety, and fatigue among women with breast cancer. J Psychosoc Oncol. 2005;23(2-3):137–57.
    1. Laviolette M, Cormier Y, Loiseau A, Soler P, Leblanc P, Hance AJ. Bronchoalveolar mast cells in normal farmers and subjects with farmer's lung. Diagnostic, prognostic, and physiologic significance. Am Rev Respir Dis. 1991 Oct;144(4):855–60. doi: 10.1164/ajrccm/144.4.855.
    1. Fu MR, Chen CM, Haber J, Guth AA, Axelrod D. The effect of providing information about lymphedema on the cognitive and symptom outcomes of breast cancer survivors. Ann Surg Oncol. 2010 Jul;17(7):1847–53. doi: 10.1245/s10434-010-0941-3.
    1. Stanton Anthony W B. Modi S, Mellor RH, Levick JR, Mortimer PS. Recent advances in breast cancer-related lymphedema of the arm: lymphatic pump failure and predisposing factors. Lymphat Res Biol. 2009;7(1):29–45. doi: 10.1089/lrb.2008.1026.
    1. McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee Kimberly J Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008 Nov 10;26(32):5213–9. doi: 10.1200/JCO.2008.16.3725.
    1. Fu MR. Breast cancer-related lymphedema: Symptoms, diagnosis, risk reduction, and management. World J Clin Oncol. 2014 Aug 10;5(3):241–7. doi: 10.5306/wjco.v5.i3.241.
    1. Ridner SH, Fu MR, Wanchai A, Stewart BR, Armer JM, Cormier JN. Self-management of lymphedema: a systematic review of the literature from 2004 to 2011. Nurs Res. 2012;61(4):291–9. doi: 10.1097/NNR.0b013e31824f82b2.
    1. Fu MR, Axelrod D, Guth AA, Cartwright F, Qiu Z, Goldberg JD, Kim J, Scagliola J, Kleinman R, Haber J. Proactive approach to lymphedema risk reduction: a prospective study. Ann Surg Oncol. 2014 Oct;21(11):3481–9. doi: 10.1245/s10434-014-3761-z.
    1. Cemal Y, Pusic A, Mehrara B. Preventative measures for lymphedema: separating fact from fiction. J Am Coll Surg. 2011 Oct;213(4):543–51. doi: 10.1016/j.jamcollsurg.2011.07.001.
    1. McLaughlin SA, Bagaria S, Gibson T, Arnold M, Diehl N, Crook J, Parker A, Nguyen J. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2013 Mar;216(3):380–9; quiz 511. doi: 10.1016/j.jamcollsurg.2012.11.004.
    1. The-Optimal-Lymph-Flow™. [2015-10-22].    .
    1. Gureje O, Simon GE, Von KM. A cross-national study of the course of persistent pain in primary care. Pain. 2001 May;92(1-2):195–200.
    1. Eysenbach G. CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res. 2011;13(4):e126. doi: 10.2196/jmir.1923.
    1. Fu M, Axelrod D, Guth A, Fletcher J, Qiu J, Scagliola J, Kleinman R, Ryan C, Chan N, Haber J. Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study. JPM. 2015 Sep 03;5(3):326–340. doi: 10.3390/jpm5030326.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit